Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook

What happened: Merck & Co., Inc. MRK reported third-quarter 2026 results and raised its full-year sales and earnings outlook, citing oncology demand and pipeline progress. Key numbers: Non-GAAP EPS $2.49 vs $2.12 estimate, down 3.5% year over year. Revenue $18.09 billion, up 4.7%. Why it matters: Management expects modest 2027 revenue growth, with more than $2 billion in headwinds from generic competition and patent expirations affecting BRIDION, JANUVIA and Adempas, and KEYTRUDA growth moderating as penetration approaches peak levels. Market: +2.3% today ($149.69), +41.7% YTD, 0.2x vol — as of 14:17 UTC Verified: Q3_2026 (Oct 29) EPS $2.49 vs $2.09 est, +19.3% beat; next print ~Jan 28

Merck & Co., Inc. MRK reported third-quarter 2026 results and raised its full-year sales and earnings outlook, citing oncology demand and pipeline progress.

Management expects modest 2027 revenue growth, with more than $2 billion in headwinds from generic competition and patent expirations affecting BRIDION, JANUVIA and Adempas, and KEYTRUDA growth moderating as penetration approaches peak levels. Market: +2.3% today ($149.69), +41.7% YTD, 0.2x vol — as of 14:17 UTC Verified: Q3_2026 (Oct 29) EPS $2.49 vs $2.09 est, +19.3% beat; next print ~Jan 28